第27屆台灣癌症聯合學術年會 (TJCC 2023)

By /

Day 1 Keynote Speech 大會專題演講連結 (2023/05/06 六)

  1. Clinical Applications and Translational Opportunities of Circulating Tumor DNA in Oncology (Prof Siu, Lillian L)
  2. 從血液病理、病毒與癌症研究、到新藥開發的心路歷程 The career research trip from leukemia/lymphoma, virus-associated cancers, to new drug development. (Prof Su, IJ)

Day 1 PM 中華民國癌症醫學會 05/06 議程

  1. Metabolism in cancer and immune regulation (林慧觀院士 Hui-Kuan (Kelvin) Lin Duke University)
  2. Shaping of the tumor microenvironment by Globo H ceramide 陳鈴津院士 Alice L. Yu 林口長庚紀念醫院幹細胞與轉譯癌症研究所)
  3. Chien-Tien Hsu’s Outstanding Cancer Research Award 徐千田癌症研究傑出獎頒獎暨專題演講（獲獎人：葉坤輝教授）
  4. Chien-Tien Hsu’s Outstanding Cancer Research Award 徐千田癌症研究傑出獎頒獎暨專題演講（獲獎人：蘇文彬教授）
  5. Drug Design and Development: Explore the therapeutic potential of a novel targeting–NHRI 岳嶽硏究員
  6. Drug Design and Development: Synergistic Effects of ABT-301, a pan-HDAC inhibitor, on Colon Cancer Treated with Immunotherapy–NHRI 徐祖安 教授
  7. Drug Design and Development: Neoantigen-based precision immune cell therapy against solid tumors, 林口長庚醫院 洪舜郁 教授

Day 2 中華民國癌症醫學會議程 (本土臨床試驗Domestic Clinical Trials)

  1. 9:00–9:50 董大成博士癌症基礎醫學研究 (Ta-Cheng Tung’s Basic Cancer Research) 傑出獎頻獎暨主題演講（獲獎人：沈延盛教授： Tumor-associated macrophages promote resistance of hepatocellular carcinoma cells against sorafenib by activating CXCR2 signaling ）
  2. 9:50–10:00 開幕致詞 (楊慕華 國立陽明交通大學副校長)
  3. 10:00–10:20 Modulation of tumor microenvironment for improving immunotherapy efficacy (國衛院主任秘書 洪文俊特聘研究員)
  4. 10:20–10:40 Revolutionizing and Beckoning of New Era of mRNA Cancer Therapeutic Vaccin and Immunotherapy (林錦洲 醫師Carios Linn, MD, Global Lead Clinician, Sr. Director, Oncology (Immuno-Oncology) Global Product Development, Pfizer, Inc.; Moderator 饒坤銘副院長 義大癌治療醫院內科)
  5. 10:50–11:00 ADCs with site-specific conjugation of cytotoxic drug bundles for homogeneity and high DAR ( 朱鑫懋博士Hsin-Mao Chu, 免疫功坊股份有限公司 研發部 Vice President of R&D, Immunwork. Inc.)
  6. 11:10–11:30 The development of allogeneic off-the-shelf CAR-T and CAR-NK (林建廷 醫師 Chien-Tina Lin, Anbogen Therapeutics Inc., Senior medical advisor, Anbogen Therapeutics Ins.)
  7. 11:30–11:50 Innovative Clinical Trial Designs for Cancer Therapies (Sr. Prindipal Statistical Scientist, Ph.D.; Moderator Ray Lin 顏家瑞 主任 Chia-Jui Yen, 成大院癌症中心 Cancer Center, National Cheng Kung University)

Day 3 中華民國癌症醫學會議程 (ESMO-TOS Joint Session) Antibody-Drug Conjugate Drugs (ADC)

  1. 9:40–10:00 Egbert Smit (Pulmonary Medicine. Netherlands Cancer Institute, Netherlands)
  2. 10:00–10:20 ADC in breast cancer 盧彥伸 教授 (Ven-Shen Lu, 喜灣大學附設醫院腫瘤醫學部 Department of Oncology, NTUH)
  3. 10:40–11:00 ADC in urothelial cancers, Yohann Loriot (Medical Oncology, Gustave Roussy Institute, University Paris-Saclay, Villejuif, France)
  4. 11:00–11:20 DC in hematological malignancy (葉士芃 主任 Su-Peng Yeh, 中國醫藥大學附設醫院 血液腫瘤科; moderator 邱昌芳 院長)
Scroll to Top